G
Generation Bio
Engages in developing genetic medicines through gene therapy platform for intrinsic hepatic diseases and systemic diseases
At a glance
- Status
- Listed
- Listing
- IPO 2020
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
1k+ Global Genetics & Genomics startups
Market map
Companies building biology-native data infrastructure
Apr 30, 2026
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in United States
Analysis
Moderna vs BioNTech: minority investments
Sep 11, 2026
Open roles
Generation Bio in the Cambridge ecosystem
The Generation Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later10 investors entered at this stage
- TCTransformation Capital
T. Rowe Price
Casdin Capital- DEDeerfield
Wellington Management
Fidelity Investments- INInvus
Foresite Capital- NHNational Institutes of Health
- FMFarallon Capital Management
Source: Dealroom Talent Intelligence.
Alumni founders
Former Generation Bio employees who went on to found companies, sorted by Dealroom signal score.
DTDyne TherapeuticsEst. 2017
Phillip SamayoaUnited States
UBUmoja BiopharmaEst. 2019
Andy ScharenbergUnited States
CBCarbon BiosciencesEst. 2021
TNTortugas NeuroscienceEst. 2024Patents
48 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Generation Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
XOMA acquires Generation Bio (February 2026)